Meiji Yasuda America Inc Buys Shares of 12,816 Insulet Corporation $PODD

Meiji Yasuda America Inc bought a new stake in shares of Insulet Corporation (NASDAQ:PODD) during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm bought 12,816 shares of the medical instruments supplier’s stock, valued at approximately $3,643,000.

Several other institutional investors also recently bought and sold shares of the stock. Vanguard Group Inc. raised its holdings in Insulet by 1.0% during the third quarter. Vanguard Group Inc. now owns 8,796,200 shares of the medical instruments supplier’s stock valued at $2,715,651,000 after buying an additional 87,845 shares in the last quarter. Geode Capital Management LLC raised its holdings in Insulet by 2.1% during the fourth quarter. Geode Capital Management LLC now owns 2,006,413 shares of the medical instruments supplier’s stock valued at $568,274,000 after buying an additional 41,019 shares in the last quarter. Norges Bank bought a new position in Insulet during the fourth quarter valued at about $300,794,000. Goldman Sachs Group Inc. raised its holdings in Insulet by 1.4% during the fourth quarter. Goldman Sachs Group Inc. now owns 768,066 shares of the medical instruments supplier’s stock valued at $218,315,000 after buying an additional 10,254 shares in the last quarter. Finally, Northern Trust Corp raised its holdings in Insulet by 0.5% during the third quarter. Northern Trust Corp now owns 709,180 shares of the medical instruments supplier’s stock valued at $218,945,000 after buying an additional 3,618 shares in the last quarter.

Insider Activity at Insulet

In other news, Director Timothy C. Stonesifer purchased 2,790 shares of the stock in a transaction that occurred on Wednesday, June 3rd. The shares were purchased at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the completion of the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. The trade was a 44.63% increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Insiders own 0.36% of the company’s stock.

Insulet Trading Down 1.0%

Insulet stock opened at $149.19 on Friday. The company has a debt-to-equity ratio of 0.71, a quick ratio of 1.81 and a current ratio of 2.49. The business’s 50-day simple moving average is $171.07 and its 200-day simple moving average is $233.25. The firm has a market capitalization of $10.33 billion, a PE ratio of 34.70, a PEG ratio of 1.19 and a beta of 1.13. Insulet Corporation has a 52 week low of $140.63 and a 52 week high of $354.88.

Insulet (NASDAQ:PODD) last posted its quarterly earnings data on Wednesday, May 6th. The medical instruments supplier reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.19 by $0.23. The business had revenue of $761.70 million for the quarter, compared to analyst estimates of $729.89 million. Insulet had a return on equity of 26.87% and a net margin of 10.44%.The firm’s revenue for the quarter was up 33.9% on a year-over-year basis. During the same period in the previous year, the company posted $1.02 earnings per share. Insulet has set its FY 2026 guidance at 6.210- EPS. Equities research analysts forecast that Insulet Corporation will post 6.46 earnings per share for the current year.

Analysts Set New Price Targets

Several research firms have weighed in on PODD. Raymond James Financial set a $216.00 target price on Insulet in a report on Monday. TD Cowen cut their target price on Insulet from $379.00 to $294.00 and set a “hold” rating on the stock in a report on Monday, June 1st. Evercore cut their target price on Insulet from $240.00 to $200.00 in a report on Thursday, May 7th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $280.00 price objective on shares of Insulet in a research note on Wednesday, May 27th. Finally, Truist Financial set a $219.00 price objective on Insulet in a research note on Thursday. Twenty-one equities research analysts have rated the stock with a Buy rating, five have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Insulet presently has an average rating of “Moderate Buy” and an average target price of $240.78.

Insulet Profile

Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.

The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.